Furthermore, WntSI proficiently alleviates acquired resistance caused by MET amplification in EGFR‐mutated NSCLC cell line against Gefitinib in PC‐9 cells and Osimertinib in NCI‐H1975 cells with T790M mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.